10,160
Participants
Start Date
August 31, 2017
Primary Completion Date
May 2, 2018
Study Completion Date
May 9, 2018
Quadrivalent VLP Vaccine
Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
Placebo
Single dose of a Placebo
Site 228, Endwell
Site 205, Binghamton
Site 230, Norfolk
Site 227, Winston-Salem
Site 216, Charlotte
Site 221, Charlotte
Site 218, Stockbridge
Site 203, Savannah
Site 220, Hollywood
Site 217, Coral Gables
Site 212, South Miami
Site 222, Mobile
Site 209, Bristol
Site 201, Columbus
Site 207, Dakota Dunes
Site 208, Omaha
Site 225, St Louis
Site 206, Wichita
Site 224, Norfolk
Site 202, Metairie
Site 226, Fort Worth
Site 219, Fort Worth
Site 204, Austin
Site 229, Austin
Site 211, West Jordan
Site 214, Salt Lake City
Site 213, Las Vegas
Site 210, Anaheim
Site 223, Milford
Site 105, Halifax
Site 106, Truro
Site 107, Brampton
Site 110, Greater Sudbury
Site 108, Toronto
Site 109, Mirabel
Site 103, Pierrefonds
Site 101, Québec
Site 102, Québec
Site 104, Sherbrooke
Site 306, Espoo
Site 305, Helsinki
Site 310, Helsinki
Site 304, Järvenpää
Site 309, Kokkola
Site 307, Oulu
Site 303, Pori
Site 308, Seinäjoki
Site 301, Tampere
Site 302, Turku
Site 402, Berlin
Site 403, Berlin
Site 406, Berlin
Site 401, Essen
Site 404, Essen
Site 405, Hamburg
Site 702, City of Muntinlupa
Site 704, City of Muntinlupa
Site 705, City of Muntinlupa
Site 701, Manila
Site 703, Manila
Site 706, Pasay
Site 601, Bangkok
Site 603, Bangkok
Site 604, Bangkok
Site 606, Bangkok
Site 607, Bangkok
Site 605, Bangkok Noi
Site 602, Chiang Mai
Site 510, Corby
Site 507, Gillingham
Site 506, Northwood
Site 508, Romford
Site 509, Shipley
Lead Sponsor
Medicago
INDUSTRY